Switch theme
Sign up to access all valuation multiples
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
2005
n/a
Last FY Revenue $3.4M
Last FY EBITDA -$49K
$12.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Read-Gene achieved revenue of $3.4M and an EBITDA of -$49K.
Read-Gene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Read-Gene valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $3.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 93% | XXX | XXX | XXX |
| EBITDA | XXX | -$49K | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1% | XXX | XXX | XXX |
| EBIT | XXX | -$0.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -6% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.3M | XXX | XXX | XXX |
| Net Margin | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Read-Gene's stock price is PLN 4 (or $1).
Read-Gene has current market cap of PLN 46.9M (or $12.4M), and EV of PLN 48.8M (or $12.9M).
See Read-Gene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.9M | $12.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Read-Gene has market cap of $12.4M and EV of $12.9M.
Read-Gene's trades at 3.8x EV/Revenue multiple, and -262.4x EV/EBITDA.
Equity research analysts estimate Read-Gene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Read-Gene's P/E ratio is not available.
See valuation multiples for Read-Gene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.4M | XXX | $12.4M | XXX | XXX | XXX |
| EV (current) | $12.9M | XXX | $12.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -262.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -60.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -47.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 242.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRead-Gene's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Read-Gene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Read-Gene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Read-Gene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Read-Gene acquired XXX companies to date.
Last acquisition by Read-Gene was XXXXXXXX, XXXXX XXXXX XXXXXX . Read-Gene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Read-Gene founded? | Read-Gene was founded in 2005. |
| Where is Read-Gene headquartered? | Read-Gene is headquartered in Poland. |
| Is Read-Gene publicy listed? | Yes, Read-Gene is a public company listed on WAR. |
| What is the stock symbol of Read-Gene? | Read-Gene trades under RDG ticker. |
| When did Read-Gene go public? | Read-Gene went public in 2009. |
| Who are competitors of Read-Gene? | Similar companies to Read-Gene include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Read-Gene? | Read-Gene's current market cap is $12.4M |
| Is Read-Gene profitable? | Yes, Read-Gene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
